Mysterious Giants May Be a Whole New Kind of Life That No Longer Exists
Ever since their discovery more than 165 years ago, massive fossilized structures left by an organism known as Prototaxites have proven impossible to categorize.
Researchers in the UK have now suggested in a report that is yet to be peer reviewed that there's a very good reason these oddities don't fit neatly on the tree of life – they belong to a branch all of their own, with no modern equivalent.
Some 400 million years ago, the swamps of the late Silurian period would have sprouted a mix of horsetails, ferns, and other prototype plants that look positively alien today.
Among them stretched 8-meter (26-foot) tall towers that defy easy identification. Wide and branchless, researchers have variously suggested these organisms were a form of algae or ancient conifer, based on what little evidence remains.
Fossils found on the shores of Gaspé Bay in Quebec, Canada, were initially considered by geologist John William Dawson to be the remains of rotting trees, leading to his naming it 'first conifer' back in the 1850s.
Though the name stuck, confusion over the fossil's classification continued, until National Museum of Natural History paleontologist Francis Hueber confirmed in 2001 that Prototaxites was indeed most likely an enormous fungus.
That conclusion was backed up years later in 2017, by a subsequent analysis of a fossil fragment assumed to be from the peripheral region of a smaller Prototaxites species named P. taiti. This study claimed to identify textures that resembled the fertile structures of today's Ascomycota fungi.
Not everybody is convinced, however, given the possibility the distinct fragments might not have even been connected.
A yet-to-be-published study on three different P. taiti fragments, led by researchers at the University of Edinburgh, argues there's insufficient evidence to conclude Prototaxites is a fungus at all.
Through a review of microscopic anatomy and chemical analysis of its tubular structures, the team systematically eliminated each and every candidate group, leaving no modern organism it might share some kind of ancestral relationship with.
Fungi? Rejected thanks to the unique way its anatomy connects. A plant or algae? Not likely given its chemical composition. A mix of the two, such as a lichen? Not with that anatomy. Some bizarre animal? Cell walls say no chance.
"Based on this investigation we are unable to assign Prototaxites to any extant lineage, reinforcing its uniqueness," the researchers claim.
"We conclude that the morphology and molecular fingerprint of P. taiti is clearly distinct from that of the fungi and other organism preserved alongside it in the [Devonian deposit], and we suggest that it is best considered a member of a previously undescribed, entirely extinct group of eukaryotes."
What might have happened to this long-dead group of organisms is anybody's guess. Further review of the study may even return the mystifying group back to its box among ancient fungi.
Without similar specimens to relate them to, Prototaxites may simply remain a fossil anomaly – a reminder that evolution is a constant experiment, one littered with far more failures than we may ever have realized.
This research can be accessed on the pre-peer review server, bioRxiv.
Venus Flytrap Wasp: 99-Million-Year-Old Amber Reveals Bizarre New Species
Hear The First-Ever Recordings of Sharks Actively Making Noises
Mysterious Golden Orb Found at The Bottom of The Ocean
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children initiating berotralstat in the APeX-P trial, and the broad safety and efficacy outcomes observed across all age groups of patients taking ORLADEYO to prevent HAE attacks. 'These data underscore the potential of our oral, once-daily prophylactic treatment to deliver consistent, meaningful benefits for people living with HAE across all stages of life. From young children to adolescents and adults, ORLADEYO continues to show strong efficacy and tolerability, helping patients experience more days free from attacks. These clinical and real-world results give me confidence that we can continue to have a very positive impact on advancing care for all those living with HAE, regardless of their age,' said Helen Thackray, chief research and development officer at BioCryst. The following three studies are being presented at the 14th C1-Inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary from May 29–June 1, 2025. Reduction in Percentage of Days with Angioedema Symptoms Among Young Children Initiating Berotralstat – Interim Results from ApeX-P Oral Presentation - Session IV - Saturday, May 31 - 10:30 – 12:45 (12:00-12:15) The ongoing open-label APeX-P study is evaluating berotralstat in children aged 2 to 11 years with HAE. There were four weight-based cohorts. Cohort 1 from these interim results received 150 mg capsules daily, while cohorts 2–4 received daily oral granule doses of 108, 96, and 78 mg, respectively. The median age was 8 years (range: 3–11), with disease onset typically between ages 2–6 years. Prior to enrollment, patients reported a mean (SD) of 18.0 (20.5) missed school days annually due to HAE. While on berotralstat, at least half of patients were attack-free each month. The percentage of days with angioedema symptoms dropped from a mean (SD) of 11 percent (9.4 percent) during the standard-of-care period, measured pre-study, to 4.0 percent (4.7 percent) over 12 weeks, with this improvement sustained up to 48 weeks. The most common treatment emergent adverse events (TEAEs) were nasopharyngitis, upper respiratory tract infection and headache. These interim findings suggest berotralstat may help children with HAE experience fewer symptoms and a more normal daily life. Berotralstat for the Prevention of Hereditary Angioedema Attacks: Results from the Italian Expanded Access Program Oral Presentation - Session VI- Sunday, June 1 - 08:00 – 09:30 (09:00-09:15) In the Italian expanded access program (EAP), 22 patients received berotralstat free of charge until commercial availability, with an additional 12 weeks of treatment to ensure continuity. Safety was monitored throughout, and data on breakthrough attacks, disease control, and quality of life (QoL) were collected. Among 12 patients with available data, median (mean) Angioedema Control Test (AECT) scores improved from 11.5 (12.8) at baseline to 13.0 (14.0) at month three and 16.0 (14.8) at month six, indicating better disease control. Median (mean) AE-QoL total scores decreased from 45.0 (42.3) at baseline to 40.0 (37.6) at month three and 36.2 (34.0) at month six, reflecting clinically meaningful improvements in QoL. All 15 patients still enrolled at program closure transitioned to commercially available ORLADEYO. The treatment was associated with a consistently low HAE attack rate, improved disease control and a safety profile consistent with clinical trial findings. Tolerability and Effectiveness of Berotralstat for Prophylaxis in Adolescents with Hereditary Angioedema: subgroup analysis of the Berolife Study Oral Presentation - Session VI - Sunday June 1 – 08:00-9:30 (08:30-08:45) The Berolife study, a real-world observational study in France, assessed the tolerability and effectiveness of berotralstat in patients with HAE, including a subgroup of adolescents (aged 12–17) who received 150 mg once daily. The mean (SD) baseline attack rate was 1.8 (1.1) attacks/month (median: 1.8), based on the six months prior to enrolment. After six months of treatment, the median monthly attack rate decreased to 0.55 (from 2.25 at baseline), with similar reductions sustained at 12 and 18 months. TEAEs in adolescents were consistent with those seen in the overall Berolife population and in the APeX-2 and APeX-S clinical trials. These findings support berotralstat as an effective and well-tolerated long-term prophylactic option for adolescents with HAE. About ORLADEYO® (berotralstat)ORLADEYO® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older. One capsule of ORLADEYO per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. U.S. Indication and Important Safety InformationINDICATIONORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. Limitations of use The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation. IMPORTANT SAFETY INFORMATION An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent. The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C). Berotralstat is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO. ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO. The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established. There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production. To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or Please see full Prescribing Information. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding future results, performance or achievements and statements relating to ORLADEYO performance and effectiveness. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; interim results of a clinical trial do not necessarily predict final results; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay, or withdraw market approval for products and product candidates; and BioCryst's ability to successfully manage its growth and compete effectively. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's forward-looking statements. BCRXW Contact:John Bluth+1 919 859 7910jbluth@ Niamh Lyons +353 87 7745000nlyons@ in to access your portfolio
Yahoo
27-05-2025
- Yahoo
Scientists create first soft robots that can walk off machine that makes them
Scientists in Scotland have created the first soft robots that can walk straight out of the machines that make them. The flexible, four-legged devices were developed using a new 3D printing system, which could pave the way for the use of intelligent soft robotic systems with no electronic parts. Soft machines – made from compliant materials such as soft plastics – have huge potential for use in areas such as nuclear decommissioning, the biomedical sector and in space, researchers say. A lack of standardised design and manufacturing processes, expense and the need for specialist expertise has so far limited real-world use of the devices, experts say. A team from the University of Edinburgh sought to overcome these challenges by developing a low-cost, desktop 3D printing system for creating soft robots. READ MORE: Scottish tech company reveals plans to double job numbers Heriot-Watt team achieves a revolution in photonics Augmented reality tech transforming visits to Scottish castles to go global Their user-friendly setup can be assembled for less than £400 using off-the-shelf parts. The team demonstrated the capabilities of their new system by creating robots made solely from a soft plastic material and powered by air pressure. Once printed, the palm-sized devices are connected to a compressed air supply before walking out of the machine on which they were made. Building and operating the new system – known as the Flex Printer – requires little prior knowledge, with first-time users able to assemble it and begin making robots in just a few days, the team says. They have made their designs publicly available to broaden access to soft robotic technologies and to help foster collaboration and improvements to the system. Soft robot walks off machine (Image: University of Edinburgh) The findings are published in the journal Device, part of the prestigious Cell Press group of journals. The research was funded by the Engineering and Physical Sciences Research Council (EPSRC). The lead engineer on the project was Maks Gepner, with support from Jonah Mack, both PhD students in the Centre for Doctoral Training in Robotics and Autonomous Systems. The lead academic was Professor Adam A. Stokes, Head of the Institute for Bioengineering at The University of Edinburgh. Maks Gepner, of the University's Schools of Engineering and Informatics, said: 'It used to take years to figure out how to print using these materials. Using our new platform, anyone can now easily print things which were previously thought to be impossible. This is a game-changer for engineers and artists alike. 'Our hope is that this technology will help drive the next wave of research breakthroughs. Without the long-standing manufacturing and design bottlenecks holding it back, we believe soft robotics is ready to make a major real-world impact."
Yahoo
23-05-2025
- Yahoo
Aliens Might Be Talking, but Our Ears Aren't Quantum Enough to Hear Them, a Scientist Says
Here's what you'll learn when you read this story: For 75 years, scientists have consistently pondered the Fermi Paradox, which asks why we don't hear from other civilizations when there are so many Earth-like worlds in the galaxy. A recent study analyzes whether these civilizations might be using quantum communication technologies beyond our own, which could explain why we don't 'hear' them. Although interstellar quantum communication is possible, the technology to detect such communications is still far from our reach. In 1950, Enrico Fermi asked the question that all of us have likely pondered at some point in our lives: Where are all of the aliens? He wasn't the first to consider this question—Soviet sci-fi legend Konstantin Tsiolkovsky, for one, asked a similar query in some of his unpublished manuscripts—and he certainly wouldn't be the last. If anything, the question has accumulated ever greater urgency as astronomers have slowly realized that there are likely billions of Earth-like planets in our galaxy alone, and we're discovering more tantalizing, potentially-life-supporting planetary candidates all the time. This 'Fermi Paradox' has spawned dozens of theories, ideas, and hypotheses in the 75 years since. Maybe a 'Great Filter' lies in our distant past—the unlikely development of eukaryotic cells is a compelling candidate—or maybe (and this is the real bummer) it still lies ahead in our future. Are the aliens just not interested? A galaxy-spanning intelligence scoring a solid 'III' on the Kardashev Scale would likely be indifferent about a sub-I species intent on poisoning its own atmosphere. In other words, maybe we're an ant among giants. Or, maybe more simply, aliens are reaching out to us, but we're just not listening—not in the right way, at least. In a study published back in 2020 in the journal Physical Review D, University of Edinburgh physicist Arjun Berera determined that quantum communication—that is, communication that leverages photon qubits rather than the more classical radio waves we use today—could maintain what's known as coherence over interstellar distances. This idea got Berera's colleague Lantham Boyle, a fellow theoretical physicist at the University of Edinburgh, to start pondering if aliens throughout our galaxy (and beyond) could be using communication technologies outside of the classical realm (specifically quantum communication) that we simply can't hear. 'It's interesting that our galaxy (and the sea of cosmic background radiation in which it's embedded) 'does' permit interstellar quantum communication in certain frequency bands,' Boyle told back in September. This curiosity eventually led to the writing of a paper, which has been uploaded to the pre-print server arXiv, titled 'On Interstellar Quantum Communication and the Fermi Paradox.' In the paper, Boyle sets out to determine if an institute like the Search for Extraterrestrial Intelligence (SETI) could somehow incorporate quantum communication detection as part of their never-ending search for interstellar beings. While the answer to that question is technically yes, it's practically a very strong, no-bones-about-it 'no.' The problem is the size of the dish we'd need to construct in order to hear this quantum convo. For example, Boyle calculated that interstellar quantum communication would need to use wavelengths of at least 26.5 centimeters in order to avoid quantum depolarization due to the cosmic microwave background (CMB). That's all well and good, but that means that to communicate quantumly with Alpha Centauri—the nearest star to our own—we'd need a diffraction-limited telescope with a diameter of roughly 100 kilometers (60 miles), which is an area larger than the city of London. To put it mildly, SETI doesn't have that kind of budget. 'We have seen that the sender must place nearly all of their photons into our receiving telescope, which implies that the signal must be so highly directed that only the intended receiving telescope can hope to detect any sign of the communication,' Boyle wrote. 'This is in sharp contrast to classical communication, where one can broadcast photons indiscriminately into space, and an observer in any direction who detects a small fraction of those photons can still receive the message.' Of course, if such an advanced civilization is capable of overcoming these engineering challenges, it's also likely that they could just glimpse our little corner of the cosmos and know we're not technologically equipped to hear what they're sending. So, who knows? Maybe some silicon-based lifeforms orbiting a M-type star in the Large Magellanic Cloud have a regular quantum correspondence with the reigning Kardashev III civilization in Andromeda all about the peculiar apes on one particular spiral arm of the Milky Way that won't return their calls. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
